In mice treated with NRP1-specific ASOs, delayed tumor growth and complete tumor eradication were demonstrated ... upon tumor re-challenge, indicating induction of an anti-tumor memory immune response.
NOUS-209 is an off-the-shelf immunotherapy designed to target tumors with specific genetic deficiencies known as mismatch repair deficiency (dMMR) and/or microsatellite instability (MSI). These tumors ...
18 hearing, one witness actually compared unborn children to an appendix and a tumor ... It is ludicrous to propose there is no difference between an unborn child and a tumor being removed ... and a tumor.
In addition to its proprietary Amanitin-based ADC technology, Heidelberg Pharma has developed a diverse ADC toolbox designed to overcome tumor resistance through multiple mechanisms, enabling targeted treatment across various cancer types.
Their study showed that "the compound renieramycin M (RM), especially when combined with the clinically used cancer drug doxorubicin (Dox), significantly shrank tumors in mice while reducing the toxicity commonly associated with chemotherapy drugs.".
Xenetic's proprietary recombinant DNase I is an enzyme that digests NETs in a tumor microenvironment ... or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
Proton therapy focuses a targeted dose of radiation to treat tumors, in turn minimizing damage to surrounding tissue ... tumors are located on the brain, spine, heart or eyes, according to a release.
Swifties send friendship bracelets to 13-year-old with brain tumor ... The incurable and terminal disease is a rare and aggressive brain tumor found on the brain stem.
AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that forces tumor cells to present their own tumor antigens, inducing a personalized immune response tailored to target each patient’s cancer ... .
Dewpoint will present two posters at AACRCondensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancerC-mods modulate the oncogenic function of historically undruggable targets MYC and beta catenin ... .